Elevated ABCG2 levels are responsible for decreasing the intracellular accumulation and thus the efficiency of another anthraquinone derivate—hypericin—as was shown by the decreased efficacy of the hypericin-mediated treatment of adenocarcinoma cells [56,57,58]. The gene discussed is ABCG2; the disease is adenocarcinoma.